TET2 and acute myeloid leukemia: Although persistent clonal hematopoiesis after therapy might be a potential source for a relapse [24], a recent study of the Dutch–Belgian and Swiss cooperative AML study group showed that the relapse risk for persistent clones carrying DNMT3A, TET2, or ASXL1 mutations in complete hematologic remission is similar to the risk of MRD-negative patients at a median follow-up of 40 months [25].